TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating yesterday.
Phil Nadeau has given his Buy rating due to a combination of factors related to Aura Biosciences Inc’s promising clinical data. The updated results from the Phase I trial of bel-sar in non-muscle invasive bladder cancer (NMIBC) patients have shown strong efficacy, with a significant number of patients achieving complete responses after just a single low dose. This includes both intermediate and high-risk patients, which is a positive indicator of the drug’s potential effectiveness.
Additionally, the presence of immune cell infiltration in tumors and the resolution of non-target tumors suggest a possible abscopal effect, further supporting the drug’s potential. The ongoing Phase Ib/II trial, with initial data expected by the end of the year, adds to the optimism surrounding bel-sar’s development. These factors collectively underpin Nadeau’s confidence in the stock, justifying the Buy rating.
According to TipRanks, Nadeau is a 3-star analyst with an average return of 2.3% and a 42.15% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Biogen, and BioMarin Pharmaceutical.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.